At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination and to Evaluate Single Dose Pharmacokinetics of MK0524A in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia
In Brief
A Phase 1 clinical trial evaluating niacin (+) laropiprant, Comparator: aspirin, and 3 other interventions for Primary Hypercholesterolemia and Mixed Hyperlipidemia. Completed, enrolled 36 participants.
Detailed Summary
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.
Study Details
Timeline
Interventions
open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
81 mg oral tablet once daily for 7 days
75 mg oral tablet once daily for 7 days
40 mg oral tablet once daily for 7 days
placebo oral tablet once daily for 7 days